Local view for "http://purl.org/linkedpolitics/eu/plenary/2011-02-16-Speech-3-204-000"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20110216.11.3-204-000"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
"−
The falsification of medicines is an organised crime that endangers peoples’ lives just like narcotics trafficking. Nevertheless, this type of crime is neither regulated in the same way nor subject to the same level of penalties as narcotics-related crimes. Illegally producing medicines by copying, or quite simply omitting, their active ingredients does not require large-scale facilities or investment. It is easy to make a large profit. Estimated figures have revealed that proceeds from the sale of falsified medicines in 2010 exceeded EUR 50.6 million, which therefore represents a 95% increase as compared to the estimated figures five years ago. This increase is largely due to the lack of detailed legislation in some countries because of either a lack of resources or the unwillingness to implement it, and to the fact that the level of penalty set out does not have a truly deterrent effect.
I support the compromise reached by the rapporteur: it is balanced and its primary objective is to protect patients. This is a step in the right direction, even though it excludes important issues such as, for example, the fact that generic medicines and non-prescription medicines are not covered by the implementation of safety features."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples